- Home
- CHH vs RYTM Comparison
CHH vs RYTM Comparison
Compare CHH & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHH
- RYTM
- Stock Information
- Founded
- CHH 1939
- RYTM 2008
- Country
- CHH United States
- RYTM United States
- Employees
- CHH 1700
- RYTM N/A
- Industry
- CHH Hotels/Resorts
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CHH Consumer Discretionary
- RYTM Health Care
- Exchange
- CHH Nasdaq
- RYTM Nasdaq
- Market Cap
- CHH 4.9B
- RYTM 6.4B
- IPO Year
- CHH 1997
- RYTM 2017
- Fundamental
- Price
- CHH $106.90
- RYTM $96.12
- Analyst Decision
- CHH Hold
- RYTM Strong Buy
- Analyst Count
- CHH 15
- RYTM 13
- Target Price
- CHH $134.93
- RYTM $109.77
- AVG Volume (30 Days)
- CHH 453.4K
- RYTM 647.2K
- Earning Date
- CHH 11-03-2025
- RYTM 11-04-2025
- Dividend Yield
- CHH 1.08%
- RYTM N/A
- EPS Growth
- CHH 34.90
- RYTM N/A
- EPS
- CHH 6.50
- RYTM N/A
- Revenue
- CHH $797,866,000.00
- RYTM $156,287,000.00
- Revenue This Year
- CHH $100.21
- RYTM $46.10
- Revenue Next Year
- CHH $3.79
- RYTM $60.39
- P/E Ratio
- CHH $16.31
- RYTM N/A
- Revenue Growth
- CHH N/A
- RYTM 53.55
- 52 Week Low
- CHH $104.81
- RYTM $45.91
- 52 Week High
- CHH $157.86
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- CHH 35.52
- RYTM 45.09
- Support Level
- CHH $104.81
- RYTM $95.35
- Resistance Level
- CHH $108.61
- RYTM $103.07
- Average True Range (ATR)
- CHH 2.42
- RYTM 2.88
- MACD
- CHH 0.01
- RYTM -0.28
- Stochastic Oscillator
- CHH 23.50
- RYTM 18.55
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.